- Home
- BIAF vs HSDT Comparison
BIAF vs HSDT Comparison
Compare BIAF & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- HSDT
- Stock Information
- Founded
- BIAF 2014
- HSDT N/A
- Country
- BIAF United States
- HSDT United States
- Employees
- BIAF N/A
- HSDT N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BIAF Health Care
- HSDT Health Care
- Exchange
- BIAF Nasdaq
- HSDT Nasdaq
- Market Cap
- BIAF 7.6M
- HSDT 6.4M
- IPO Year
- BIAF 2022
- HSDT N/A
- Fundamental
- Price
- BIAF $0.15
- HSDT $25.00
- Analyst Decision
- BIAF Hold
- HSDT Hold
- Analyst Count
- BIAF 1
- HSDT 1
- Target Price
- BIAF N/A
- HSDT N/A
- AVG Volume (30 Days)
- BIAF 12.0M
- HSDT 1.2M
- Earning Date
- BIAF 11-13-2025
- HSDT 11-11-2025
- Dividend Yield
- BIAF N/A
- HSDT N/A
- EPS Growth
- BIAF N/A
- HSDT N/A
- EPS
- BIAF N/A
- HSDT N/A
- Revenue
- BIAF $7,681,059.00
- HSDT $295,000.00
- Revenue This Year
- BIAF N/A
- HSDT N/A
- Revenue Next Year
- BIAF $20.04
- HSDT $75.13
- P/E Ratio
- BIAF N/A
- HSDT N/A
- Revenue Growth
- BIAF 4.99
- HSDT N/A
- 52 Week Low
- BIAF $0.16
- HSDT $5.37
- 52 Week High
- BIAF $2.26
- HSDT $1,200.00
- Technical
- Relative Strength Index (RSI)
- BIAF 33.56
- HSDT 87.65
- Support Level
- BIAF $0.24
- HSDT $5.78
- Resistance Level
- BIAF $0.45
- HSDT $24.49
- Average True Range (ATR)
- BIAF 0.03
- HSDT 1.87
- MACD
- BIAF -0.01
- HSDT 2.56
- Stochastic Oscillator
- BIAF 5.79
- HSDT 96.55
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.